On the heels of his study, Dr. James Berenson an oncologist specializing in multiple myeloma —announced his latest findings and with his cancer patients, shared their challenging experiences during this pandemic.
Ruxolitinib Is Under Investigation as JAK Inhibition Strategy for Multiple Myeloma
CancerNetwork® spoke with James R. Berenson, MD, founder, medical and scientific director, and president and chief...